Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel A Pollyea

Showing results (121-130 of 148) with videos related to

Pageof 15
Sort By:
Transplantation and Cellular Therapy|April 22, 2023
Transplantation Referral Patterns for Patients with Newly Diagnosed Higher-Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia at Academic and Community Sites in the Connect® Myeloid Disease Registry: Potential Barriers to CareBenjamin Tomlinson, Marcos de Lima, Christopher R Cogle, et al.
Blood Advances|May 8, 2020
Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AMLSung Choe, Hongfang Wang, Courtney D DiNardo, et al.
Blood|December 30, 2015
Novel germ line DDX41 mutations define families with a lower age of MDS/AML onset and lymphoid malignanciesMaya Lewinsohn, Anna L Brown, Luke M Weinel, et al.
Blood|June 8, 2017
Enasidenib in mutant <i>IDH2</i> relapsed or refractory acute myeloid leukemiaEytan M Stein, Courtney D DiNardo, Daniel A Pollyea, et al.
Blood|December 5, 2018
Molecular remission and response patterns in patients with mutant-<i>IDH2</i> acute myeloid leukemia treated with enasidenibEytan M Stein, Courtney D DiNardo, Amir T Fathi, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 5, 2015
Myelodysplastic syndromes, version 2.2015Peter L Greenberg, Richard M Stone, Rafael Bejar, et al.
Biorxiv : the Preprint Server for Biology|January 7, 2026
The Nicotinamide Salvage Pathway is a Metabolic Vulnerability of High-Risk MDS Stem CellsSweta B Patel, Daniel Moskop, Steven Moriera, et al.
Cancer Discovery|January 25, 2020
Monocytic Subclones Confer Resistance to Venetoclax-Based Therapy in Patients with Acute Myeloid LeukemiaShanshan Pei, Daniel A Pollyea, Annika Gustafson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 9, 2022
A Phase I/II Open-Label Study of Molibresib for the Treatment of Relapsed/Refractory Hematologic MalignanciesMark A Dawson, Gautam Borthakur, Brian J P Huntly, et al.
Blood|October 7, 2020
Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 studyEytan M Stein, Courtney D DiNardo, Amir T Fathi, et al.
Pageof 15

Showing results (121-130 of 148) with videos related to

Sort By:
Pageof 15
Transplantation and Cellular Therapy|April 22, 2023
Transplantation Referral Patterns for Patients with Newly Diagnosed Higher-Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia at Academic and Community Sites in the Connect® Myeloid Disease Registry: Potential Barriers to CareBenjamin Tomlinson, Marcos de Lima, Christopher R Cogle, et al.
Blood Advances|May 8, 2020
Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AMLSung Choe, Hongfang Wang, Courtney D DiNardo, et al.
Blood|December 30, 2015
Novel germ line DDX41 mutations define families with a lower age of MDS/AML onset and lymphoid malignanciesMaya Lewinsohn, Anna L Brown, Luke M Weinel, et al.
Blood|June 8, 2017
Enasidenib in mutant <i>IDH2</i> relapsed or refractory acute myeloid leukemiaEytan M Stein, Courtney D DiNardo, Daniel A Pollyea, et al.
Blood|December 5, 2018
Molecular remission and response patterns in patients with mutant-<i>IDH2</i> acute myeloid leukemia treated with enasidenibEytan M Stein, Courtney D DiNardo, Amir T Fathi, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 5, 2015
Myelodysplastic syndromes, version 2.2015Peter L Greenberg, Richard M Stone, Rafael Bejar, et al.
Biorxiv : the Preprint Server for Biology|January 7, 2026
The Nicotinamide Salvage Pathway is a Metabolic Vulnerability of High-Risk MDS Stem CellsSweta B Patel, Daniel Moskop, Steven Moriera, et al.
Cancer Discovery|January 25, 2020
Monocytic Subclones Confer Resistance to Venetoclax-Based Therapy in Patients with Acute Myeloid LeukemiaShanshan Pei, Daniel A Pollyea, Annika Gustafson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 9, 2022
A Phase I/II Open-Label Study of Molibresib for the Treatment of Relapsed/Refractory Hematologic MalignanciesMark A Dawson, Gautam Borthakur, Brian J P Huntly, et al.
Blood|October 7, 2020
Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 studyEytan M Stein, Courtney D DiNardo, Amir T Fathi, et al.
Pageof 15